SGK1 and Alzheimer disease: We also performed the reverse experiment by treating control and AD neurons with the SGK1 inhibitor GSK650394 (100 nM for 72 h) and found that it did not affect the level of activated pGSK3 (both α and β) and total GSK3 (both α and β) (Fig. 9c).